Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ERAS 801

Next Previous
Drug Profile

ERAS 801

Alternative Names: ERAS-801

Latest Information Update: 01 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The Regents of the University of California
  • Developer Erasca; Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Glioblastoma
  • Preclinical CNS cancer

Most Recent Events

  • 30 Jul 2025 Jonsson Comprehensive Cancer Center plans a phase Ib trial for Glioblastoma (Recurrent, Late stage disease, Second line therapy or greater) in USA (PO) (NCT07089641)
  • 07 Apr 2025 Phase-I clinical trials in Glioblastoma (Combination therapy, Late-stage disease, Recurrent, Second-line therapy or greater) in USA (PO) (NCT06934889)
  • 28 Feb 2025 No recent reports of development identified for phase-I development in Glioblastoma(In the elderly, Recurrent, Second-line therapy or greater, In adults) in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top